Susan Duty
Overview
Explore the profile of Susan Duty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Finlay C, Jackson M, Fisher R, Bundgaard C, Rose S, Duty S
J Parkinsons Dis
. 2024 Mar;
14(2):245-259.
PMID: 38427500
Background: Increased activity across corticostriatal glutamatergic synapses may contribute to L-DOPA-induced dyskinesia in Parkinson's disease. Given the weak efficacy and side-effect profile of amantadine, alternative strategies to reduce glutamate transmission...
2.
Buhidma Y, Lama J, Duty S
Int Rev Neurobiol
. 2024 Feb;
174:99-118.
PMID: 38341233
Pain is one of the key non-motor symptoms experienced by a large proportion of people living with Parkinson's disease (PD), yet the mechanisms behind this pain remain elusive and as...
3.
Buhidma Y, Hobbs C, Malcangio M, Duty S
NPJ Parkinsons Dis
. 2023 Apr;
9(1):69.
PMID: 37100804
Pain is a key non-motor feature of Parkinson's disease (PD) that significantly impacts on life quality. The mechanisms underlying chronic pain in PD are poorly understood, hence the lack of...
4.
Lama J, Salabasidou E, Volkmann J, Kuzkina A, Duty S, Uceyler N
PLoS One
. 2022 Oct;
17(10):e0276564.
PMID: 36301901
Background: Pain is a common non-motor symptom of Parkinson`s disease (PD), however, its pathomechanism remains elusive. Objective: We aimed to investigate the local gene expression of selected proinflammatory mediators in...
5.
Clarke E, Stocki P, Sinclair E, Gauhar A, Fletcher E, Krawczun-Rygmaczewska A, et al.
Pharmaceutics
. 2022 Jul;
14(7).
PMID: 35890231
Single domain shark antibodies that bind to the transferrin receptor 1 (TfR1) on brain endothelial cells have been used to shuttle antibodies and other cargos across the blood brain barrier...
6.
Lama J, Buhidma Y, Fletcher E, Duty S
Neuronal Signal
. 2021 Dec;
5(4):NS20210026.
PMID: 34956652
Parkinson's disease (PD) is a complex, multisystem disorder characterised by α-synuclein (SNCA) pathology, degeneration of nigrostriatal dopaminergic neurons, multifactorial pathogenetic mechanisms and expression of a plethora of motor and non-motor...
7.
Fletcher E, Kaminski T, Williams G, Duty S
Pharmacol Res Perspect
. 2021 Jul;
9(4):e00841.
PMID: 34309236
Parkinson's disease is a highly disabling, progressive neurodegenerative disease that manifests as a mix of motor and non-motor signs. Although we are equipped with some symptomatic treatments, especially for the...
8.
Fletcher E, Finlay C, Lopez A, Crum W, Vernon A, Duty S
Front Neurosci
. 2020 Oct;
14:567222.
PMID: 33041762
Dyskinesia associated with chronic levodopa treatment in Parkinson's disease is associated with maladaptive striatal plasticity. The objective of this study was to examine whether macroscale structural changes, as captured by...
9.
Mann E, Jackson M, Lincoln L, Fisher R, Rose S, Duty S
J Parkinsons Dis
. 2020 Apr;
10(3):959-967.
PMID: 32250315
Background: Increased firing across glutamatergic synapses may contribute to both the motor dysfunction and L-DOPA-induced dyskinesia seen in Parkinson's disease. Given their ability to reduce glutamate release, activation of group...
10.
Buhidma Y, Rukavina K, Chaudhuri K, Duty S
NPJ Parkinsons Dis
. 2020 Jan;
6:1.
PMID: 31934609
Pain is a commonly occurring non-motor symptom of Parkinson's disease (PD). Treatment of pain in PD remains less than optimal and a better understanding of the underlying mechanisms would facilitate...